Invokana Trials Stopped Early Due To Significant Success | Latest News RSS feed

Invokana Trials Stopped Early Due To Significant Success - Latest News


Invokana trial stopped early after success in slowing kidney disease progression

The diabetes drug Invokana ... early. CREDENCE stands for Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation. "We have accepted the advice of the Independent ... read more

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings

"We have accepted the advice of the Independent Data Monitoring Committee to stop the CREDENCE trial early due to ... In addition, INVOKANA ® is not recommended when eGFR is persistently less than 45 ... read more

Gilead leukemia drug trial unblinded early due to success

Nov 16 (Reuters) - A late stage trial of a Gilead Sciences drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine ... read more

Looking for another news?


Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease

designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. The decision to stop the trials ... read more


Trulicity Label Update; Canagliflozin Success for CKD; Capsaicin for Weight Loss

The phase III CREDENCE Renal Outcomes Trial involving canagliflozin (Invokana) -- with around 4,400 patients with type 2 diabetes and kidney disease -- is being stopped early due to positive findings, ... read more

Controlling Blood Pressure Can Be Key to Easing Risk of Cognitive Impairment

Investigators from Wake Forest School of Medicine led the clinical trial on nearly 10,000 older adults with hypertension. They discovered keeping blood pressure under control has significant ... ... read more

Progenics: Why I Finally Decided To Buy

It is too early to determine if the pre-ER entry will ultimately be a success ... a significant financial deal for Progenics, but should provide confidence in the prospects for PyL due to Curium ... read more

Abeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript

After a year of intense foundational work, we're poised to deliver an important near ... establish pathways to success and bringing treatments to patients in need. At our R&D Day in December, we ... read more

Rhythm Pharma: Investible Based On Upcoming Trial Data

Genetic early onset obesity and its related syndromes is the same disease area where Zafgen’s Beloranib once failed to achieve success ... What is most important is that safety profile was pretty mild ... read more

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings

"We have accepted the advice of the Independent Data Monitoring Committee to stop the CREDENCE trial early due to ... In addition, INVOKANA [®] is not recommended when eGFR is persistently less than ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us